BRPI0416700A - métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit - Google Patents

métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit

Info

Publication number
BRPI0416700A
BRPI0416700A BRPI0416700-7A BRPI0416700A BRPI0416700A BR PI0416700 A BRPI0416700 A BR PI0416700A BR PI0416700 A BRPI0416700 A BR PI0416700A BR PI0416700 A BRPI0416700 A BR PI0416700A
Authority
BR
Brazil
Prior art keywords
weight
methods
individual
weight loss
kit
Prior art date
Application number
BRPI0416700-7A
Other languages
English (en)
Inventor
John C Seed
Original Assignee
Theracos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theracos Inc filed Critical Theracos Inc
Publication of BRPI0416700A publication Critical patent/BRPI0416700A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS PARA TRATAR OBESIDADE, PARA ALCANçAR PERDA DE PESO DESEJáVEL, PARA EVITAR GANHO DE PESO INDESEJáVEL, E PARA FACILITAR A PERDA DE PESO EM UM INDIVìDUO NãO SOFRENDO DE DEPRESSãO, MéTODOS DE MANUTENçãO DE UM PESO ESTáVEL E DE REDUçãO DO PESO CORPORAL EM UM INDIVìDUO, COMPOSIçãO FARMACêUTICA, E, KIT". São fornecidos métodos de alcance de perda de peso desejável em um indivíduo acima do peso ou obeso pela administração de pelo menos um agente anti-colinesterase e de pelo menos um antidepressivo. A presente invenção também fornece composições farmacêuticas e kits para a liberação simultânea de pelo menos um agente anti-colinesterase e pelo menos um antidepressivo.
BRPI0416700-7A 2003-11-19 2004-11-19 métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit BRPI0416700A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52361003P 2003-11-19 2003-11-19
US10/993,496 US20050143350A1 (en) 2003-11-19 2004-11-18 Combination drug therapy to treat obesity
PCT/US2004/038981 WO2005051297A2 (en) 2003-11-19 2004-11-19 Combination drug therapy to treat obesity

Publications (1)

Publication Number Publication Date
BRPI0416700A true BRPI0416700A (pt) 2007-03-06

Family

ID=34636478

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416700-7A BRPI0416700A (pt) 2003-11-19 2004-11-19 métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit

Country Status (11)

Country Link
US (1) US20050143350A1 (pt)
EP (1) EP1684712A4 (pt)
JP (1) JP2007511611A (pt)
KR (1) KR20060109493A (pt)
AU (1) AU2004293008A1 (pt)
BR (1) BRPI0416700A (pt)
CA (1) CA2545655A1 (pt)
IL (1) IL175615A0 (pt)
RU (2) RU2363458C2 (pt)
SG (1) SG148169A1 (pt)
WO (1) WO2005051297A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
CA2555386A1 (en) * 2004-02-19 2005-09-01 Novartis Ag Use of cholinesterase inhibitors for treating vascular depression
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
AU2006209216A1 (en) * 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CA2616858A1 (en) * 2005-07-27 2007-02-01 Carlos Henrique Horta Lima Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties.
SI1942891T1 (sl) * 2005-09-22 2011-06-30 Eisai R&D Man Co Ltd Nova kombinacija zdravil kot antidepresiv
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
KR101408488B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
EP2098232B1 (en) * 2006-12-01 2013-06-05 Nitto Denko Corporation Percutaneous absorption preparation
CA2704728A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
JP2011521914A (ja) * 2008-05-19 2011-07-28 ネステク ソシエテ アノニム 動物による脂質吸収を抑制する方法
CA2724502A1 (en) * 2008-05-30 2009-12-03 Nitto Denko Corporation Adhesive preparation containing donepezil, and package of the same
CN102046171B (zh) * 2008-05-30 2013-06-19 日东电工株式会社 经皮吸收制剂
US8633252B2 (en) * 2009-01-26 2014-01-21 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
PT2501234T (pt) 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
WO2011163231A2 (en) 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US20130324609A1 (en) * 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
WO2012050348A2 (ko) * 2010-10-13 2012-04-19 한국과학기술원 역률보상형 엘이디 조명장치
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
CA2829200C (en) * 2011-03-07 2022-05-03 Tonix Pharmaceuticals, Inc. Methods and compositions for treating depression using cyclobenzaprine
TWI740136B (zh) 2013-03-15 2021-09-21 愛爾蘭商托尼克製藥控股有限公司 環苯扎林鹽酸鹽及阿密替林鹽酸鹽之共晶調配物
US20150157672A1 (en) * 2013-12-09 2015-06-11 Phytology Labs, Inc. Kits and methods for sustained weight loss
EP3102227A4 (en) 2014-02-07 2017-09-27 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline
JP6614724B2 (ja) 2014-09-18 2019-12-04 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
US20190175610A1 (en) * 2017-12-07 2019-06-13 Glykon Technologies Group, Llc Formulation of galantamine and carnitine and method of fatty acid mobilization
AU2018383098A1 (en) 2017-12-11 2020-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3673177A (en) * 1970-05-04 1972-06-27 American Cyanamid Co Substituted 4-(anilinomethylene)-3-galanthamaninones
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4895845A (en) * 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5312817A (en) * 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
EP0567090B1 (en) * 1992-04-24 2000-07-26 Takeda Chemical Industries, Ltd. Benzoxazepine derivatives as cholinesterase inhibitors
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
TW248556B (pt) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
ATE213407T1 (de) * 1993-06-28 2002-03-15 American Home Prod Neue behandlungsmethoden durch verwendung von phenethylderivaten
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
PL335619A1 (en) * 1997-03-11 2000-05-08 Darwin Discovery Ltd Dosage forms including separate parts containing r and s enantiomers
EP0975624A1 (en) * 1997-04-17 2000-02-02 Takeda Chemical Industries, Ltd. Thermogenic composition and benzazepine thermogenics
US5795895A (en) * 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
US6313919B1 (en) * 1997-07-02 2001-11-06 Canon Kabushiki Kaisha Printing control apparatus and method
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
PT1158973E (pt) * 1999-02-24 2005-07-29 Univ Cincinnati Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6688640B1 (en) * 1999-08-17 2004-02-10 Lear Corporation Tethered air bag cover
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US20010043957A1 (en) * 2000-02-25 2001-11-22 Morris Mann Lypolytic composition
EP1132389A1 (en) * 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
US6533540B1 (en) * 2000-06-09 2003-03-18 Sta-Rite Industries, Inc. Double-seal/oil-reservoir system for a motor/pump assembly
FI20011621A (fi) * 2000-08-18 2002-02-19 Lundbeck & Co As H Menetelmä sitalopraamin valmistamiseksi
ES2194597B2 (es) * 2002-01-25 2004-08-01 Esteve Quimica, S.A. Procedimiento para la obtencion de citalopram.

Also Published As

Publication number Publication date
WO2005051297A2 (en) 2005-06-09
WO2005051297A3 (en) 2006-07-20
EP1684712A2 (en) 2006-08-02
SG148169A1 (en) 2008-12-31
AU2004293008A1 (en) 2005-06-09
EP1684712A4 (en) 2009-04-22
US20050143350A1 (en) 2005-06-30
KR20060109493A (ko) 2006-10-20
RU2009113038A (ru) 2010-10-20
RU2006121453A (ru) 2008-01-10
JP2007511611A (ja) 2007-05-10
IL175615A0 (en) 2008-04-13
RU2363458C2 (ru) 2009-08-10
CA2545655A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
BRPI0416700A (pt) métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
DZ3221A1 (fr) Nouvelles compositions estro-progestatives topiques a effet systemique
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
BR0113400A (pt) Método para seleção de peptìdeo
BR0200155A (pt) Tratamento combinado para depressão
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
BRPI0510909A2 (pt) composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
DE60115274D1 (de) Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
BRPI0416933A (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente
BRPI0418854A (pt) composições herbáceas
BRPI0410707A (pt) composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios
BRPI0415163A (pt) composição de xampu e usos de uma combinação de cera de abelha e silicone
DK1453520T3 (da) Sammensætning af östrogen og andre hormoner med askorbinsyre, lysin, prolin og andre stoffer
BRPI0407039A (pt) Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose
BR0111378A (pt) Kits e métodos para otimizar a eficácia de composições, condriprotetoras
BR0210975A (pt) Composição oral para uso como um agente profilático, terapêutico e/ou cosmético para a obesidade/excesso de peso em mamìferos não diabéticos, inclusive em seres humanos e preparação de uma composição oral
BR0314821A (pt) Derivado de piperidina, composição farmacêutica, uso do derivado de piperidina, e, método para tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.